Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Zogenix’s Fintepla projected to reach $872m by 2026 despite recent setback

The FDA recently rejected a marketing application for Zogenix’s Fintepla, an anti-epileptic drug candidate for Dravet syndrome. Magdalene Crabbe, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, discusses the revelation: “The impact of this setback is not necessarily catastrophic. Fintepla is still at the pre-registration stage in the EU and in […]
Read more

Louisiana achieves major discount from Gilead’s subsidiary through Hepatitis C procurement model

Louisiana’s Department of Health recently announced that Gilead’s subsidiary Asegua Therapeutics has been selected as the pharmaceutical company for hepatitis C procurement model. Arafa Salam, PhD, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the cost savings realized by this innovative procurement strategy: “The strong competition for patient share […]
Read more

UCB’s Cimzia US approval for nr-axSpA places company ahead of competitive biologic space

The approval of UCB’s Cimzia marks the first anti-tumor necrosis factor biologic therapy for non-radiographic axial spondyloarthritis (nr-axSpA) patients in the US, having been already approved for the condition in Europe. Antoine Grey, MBiochem, Immunology Analyst at GlobalData, a leading data and analytics company, offers his view: “UCB’s efforts to expand into a patient population […]
Read more

Sleep boosting DNA repair in damaged neurons could significantly impact the treatment of mental illnesses

A recent study conducted at Bar-Ilan University in Israel found that DNA repair in damaged neurons is most efficient during sleep, and treating sleep disorders is a vastly growing area of innovation in the pharmaceutical industry. Magdalene Crabbe, Neurology and Ophthalmology Analyst at GlobalData, a leading data and analytics company, discusses the revelation: “Considering the […]
Read more

The flow diversion stent market is growing at a CAGR of approximately 2%

Estimated to be approximately 15% of the embolization devices market, the flow diversion stent market is growing at a Compound Annual Growth Rate (CAGR) of approximately 2% by 2028, says GlobalData. In February, “Medtronic’s Pipeline Flex flow diversion device” won expanded FDA approval to treat small or medium wide-neck aneurysms, in addition to its existing […]
Read more

Despite two cases of remission, effective HIV cure is still years away

Following the news of a UK patient (The London Patient) who has been in remission with undetectable levels of HIV viral load for 18 months, becoming the second patient who has experienced disease free remission from HIV, Patrick Aiyes, MEng, Immunology Analyst at GlobalData, a leading data and analytics company comments: “The London Patient, similar […]
Read more

Tecentriq assumes pole position with FDA approval but Keytruda looms in triple negative breast cancer

On March 8, the FDA granted the accelerated approval of Roche’s programmed cell death protein 1 (PD-1) inhibitor Tecentriq in combination with Abraxane (protein-bound paclitaxel) for the treatment of locally advanced or metastatic triple-negative breast cancer (TNBC). Adam Pearson, PhD, Oncology and Hematology Analyst at GlobalData, a leading data and analytics company, offers his view […]
Read more

Roche’s acquisition of Spark Therapeutics is a long-term investment in the hemophilia A gene therapy market

Following the news (25 February 2019) that Roche has entered into a definitive merger agreement to fully acquire Spark Therapeutics for $4.3bn, Tajekesa Chapman, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view on the acquisition: “The hemophilia market is currently undergoing major changes in its treatment landscape due to advances […]
Read more

Merck’s Keytruda set to become new standard of care for renal cancer patient population after gaining edge over competitors

Merck & Co Inc’s abstract presentation regarding KEYNOTE-426 trial at ASCO GU 2019 (16 February 2019) has confirmed that Keytruda, an anti-PD-1 therapy, in combination with Pfizer’s Inlyta, a tyrosine kinase inhibitor, can significantly improve clinical outcomes for renal cancer patients. Amrita Gujral, Pharma Analyst at GlobalData, a leading data and analytics company, offers her […]
Read more
1 … 107 108 109 110